H

Hubei Jumpcan Pharmaceutical Co Ltd
SSE:600566

Watchlist Manager
Hubei Jumpcan Pharmaceutical Co Ltd
SSE:600566
Watchlist
Price: 30.09 CNY 2.24% Market Closed
Market Cap: 27.6B CNY
Have any thoughts about
Hubei Jumpcan Pharmaceutical Co Ltd?
Write Note

Wall Street
Price Targets

Price Targets Summary
Hubei Jumpcan Pharmaceutical Co Ltd

Wall Street analysts forecast Hubei Jumpcan Pharmaceutical Co Ltd stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Hubei Jumpcan Pharmaceutical Co Ltd is 53.41 CNY with a low forecast of 52.88 CNY and a high forecast of 54.98 CNY.

Lowest
Price Target
52.88 CNY
76% Upside
Average
Price Target
53.41 CNY
77% Upside
Highest
Price Target
54.98 CNY
83% Upside
Hubei Jumpcan Pharmaceutical Co Ltd Competitors:
Price Targets
SNT
Syntara Ltd
83% Upside
1666
Tong Ren Tang Technologies Co Ltd
28% Upside
ROVI
Laboratorios Farmaceuticos ROVI SA
51% Upside
4554
Fuji Pharma Co Ltd
45% Upside
600867
Tonghua Dongbao Pharmaceutical Co Ltd
38% Upside
603707
Nanjing King-friend Biochemical Pharmaceutical Co Ltd
58% Upside
4746
Formosa Laboratories Inc
63% Upside

Revenue
Forecast

Revenue Estimate
Hubei Jumpcan Pharmaceutical Co Ltd

For the last 8 years the compound annual growth rate for Hubei Jumpcan Pharmaceutical Co Ltd's revenue is 12%. The projected CAGR for the next 3 years is 3%.

12%
Past Growth
3%
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Hubei Jumpcan Pharmaceutical Co Ltd

For the last 8 years the compound annual growth rate for Hubei Jumpcan Pharmaceutical Co Ltd's operating income is 19%. The projected CAGR for the next 3 years is 8%.

19%
Past Growth
8%
Estimated Growth
Estimates Accuracy
0%
Average Beat

Net Income
Forecast

Net Income Estimate
Hubei Jumpcan Pharmaceutical Co Ltd

For the last 8 years the compound annual growth rate for Hubei Jumpcan Pharmaceutical Co Ltd's net income is 19%. The projected CAGR for the next 3 years is 7%.

19%
Past Growth
7%
Estimated Growth
Estimates Accuracy
-6%
Average Miss

See Also

Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is Hubei Jumpcan Pharmaceutical Co Ltd's stock price target?
Price Target
53.41 CNY

According to Wall Street analysts, the average 1-year price target for Hubei Jumpcan Pharmaceutical Co Ltd is 53.41 CNY with a low forecast of 52.88 CNY and a high forecast of 54.98 CNY.

What is Hubei Jumpcan Pharmaceutical Co Ltd's Revenue forecast?
Projected CAGR
3%

For the last 8 years the compound annual growth rate for Hubei Jumpcan Pharmaceutical Co Ltd's revenue is 12%. The projected CAGR for the next 3 years is 3%.

What is Hubei Jumpcan Pharmaceutical Co Ltd's Operating Income forecast?
Projected CAGR
8%

For the last 8 years the compound annual growth rate for Hubei Jumpcan Pharmaceutical Co Ltd's operating income is 19%. The projected CAGR for the next 3 years is 8%.

What is Hubei Jumpcan Pharmaceutical Co Ltd's Net Income forecast?
Projected CAGR
7%

For the last 8 years the compound annual growth rate for Hubei Jumpcan Pharmaceutical Co Ltd's net income is 19%. The projected CAGR for the next 3 years is 7%.

Back to Top